US/UK/Canada

Share

About Us

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit professional organization with more than 2,700 members from over 45 countries dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy. For more information, visit www.ishlt.org.

Pick a time period -
Tags ( Active)

RESULTS FROM LUNG TRANSPLANT DRUG THERAPY TRIAL REVEAL EXPECTED BUT APPEALING FINDINGS

DONOR LUNG MANAGEMENT TRIAL (INSPIRE) UPDATE TO BE PRESENTED TODAYPRAGUE, Czech Republic, April 20, 2012 –Results of a three-year international study of drug therapy for lung transplant patients will be presented today by Allan Glanville, M.D., Professor and Medical Director Lung Transplantation, Director Thoracic Medicine, at St. Vincent's Hospital in Darlinghurst, Australia, during the International Society for Heart and Lung Transplantation (ISHLT) 32nd Annual Meeting and Scientific Sessions in Prague, Czech Republic. There are currently no therapies which prevent obliterative

INTERNATIONAL EXPERTS ADDRESS CHALLENGES OF DRUG-RESISTANT INFECTION IN HEART AND LUNG TRANSPLANT POPULATION

Discussions to address strategies to prevent and treat infection of multi-drug resistant strainsPrague, Czech Republic, April 20, 2012 – Drug-resistant infections are an increasing worldwide problem contributing to significant mortality and morbidity in heart and lung transplant patients. Due to globalization these infections spread and pass geographic barriers easily. It has become apparent that the epidemiology of these infections and how they are best treated is an evolving issue—one that is more complicated than maybe first realized. Multi-Drug-Resistant infections will be addressed

NEW DATA RELEASED AT ISHLT MEETING MAY IMPACT TREATMENT FOR PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

PRAGUE, Czech Republic, April 19, 2012 – An initial report from the EPITOME-1 (Epoprostenol for Injection in Pulmonary Arterial Hypertension) study of a new formulation of the drug therapy epoprostenol, marketed as Flolan® will be revealed today at the International Society for Heart and Lung Transplantation (ISHLT) 32nd Annual Meeting and Scientific Sessions in Prague, Czech Republic. The findings could potentially allow patients living with Pulmonary Arterial Hypertension (PAH) to avoid the need for using ice packs to prepare and store up to seven days worth of medication in the

There are no items matching the current filter
There are no more items matching the current filter
Back to top